search
Back to results

Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments

Primary Purpose

Cancer, Breast

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Neuropsychological treatment
Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).
Waitlist group
Sponsored by
Universidad de Córdoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cancer, Breast focused on measuring Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), cognitive impairments, quality of life, anxiety and depression.

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Cancer diagnosis, stages I-III.
  • Cancer type: Breast.
  • Have received the last chemotherapy session in the last 6 months and a maximum of 6 years of treatment completion.
  • Probable or mild to moderate cognitive impairment (score between 26 and 10 points according to the MMSE).
  • Ability to be fluent in Spanish.
  • Not currently participating in another clinical trial.
  • Not currently receiving other psychological treatment

Exclusion Criteria:

  • Men and women aged > 70 years.
  • Diagnosis of cancer, stage IV or other types of cancer.
  • Last chemotherapy session < 6 months or > 6 years.
  • No cognitive impairment (MMSE score between 30 and 27 points).
  • Diagnosis of mental disorder (including substance abuse) prior to cancer diagnosis.
  • Relapse in disease after chemotherapy treatment is completed.
  • Neurodevelopmental Disorder Diagnosis.
  • Diagnosis of diseases that affect cognitive performance such as: hypertension, cardiac diseases, epilepsy, dementias, multiple sclerosis, functional disorders (fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, post-concussion syndrome, whiplash syndrome), CNS infections (HIV, encephalitis), metabolic disorders (diabetes, B12 deficiency), obstructive sleep apnea, brain damage (stroke, TBI, CNS cancer) and use of medications / substances that interfere with cognitive function such as pregabalin, gabapentin, topiramate, antidepressants tricyclics, sodium valproate, anticholinergics, methylphenidate, typical antipsychotics.

Sites / Locations

  • Hospital Universitario Reina Sofía
  • Reina Sofía University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Other

Arm Label

Neuropsychological treatment

Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).

Waitlist group

Arm Description

Combination of different neuropsychological rehabilitation programs

This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED).

The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.

Outcomes

Primary Outcome Measures

Functional assessment of Cancer Therapy-Cognitive Function, version 3. (FACT-Cog).
This is an instrument developed to assess chemotherapy-induced cognitive problems in cancer patients. It includes four different subscales: Perceived Cognitive Impairments (score range from 0-72), Impact of Perceived Cognitive Impairments on QoL (score range from 0-16), Comments from Others (score range from 0-16), and Perceived Cognitive Abilities (scores range from 0-28) that are scored using a Likert scale of five points from 0 (never) to 4 (several times a day). The higher the score, the better the cognitive function
Memory Failures Everyday (MFE-30).
It is a unifactorial questionnaire that measures a single construct: "cognitive complaints". It is made up of 30 items that are answered on a 5-point Likert scale from 1 (never) to 4 (always or almost always) with higher scores indicate poorer memory function. Scores are from 1 to with higher scores indicating higher memory impairments
Hopkins Verbal Learning Test-Revised (HVLT-R).
This test measures primary and secondary memory, the rate of verbal learning throughout three trials, as well as three forms of mnesic organization: serial ordering, semantic grouping, and subjective organization. The test consists of a list of 12 words that are presented orally at a speed of one word for every two seconds. a higher number of words is interpreted as better recall and recognition
Trail Making Test (TMT).
The TMT consists of two parts: Part A measures attention, processing speed, visual search, and working memory; on the other hand, part B is used to measure attention, executive function (cognitive flexibility, ability to change tasks, coordination of categories), working memory, visual-motor skills and processing speed. A greater time to complete the tasks is interpreted as a greater deterioration
Controlled Oral Word Association Test (COWAT).
The COWAT is a test that measures verbal fluency and is a recognized and sensitive indicator of cognitive functioning. the participant has to say as many words as possible in one minute, and a greater number of words is associated with greater verbal fluency.

Secondary Outcome Measures

Hospital Anxiety and Depression Scale (HADS)
This scale is used to assess anxiety and depression in a hospital settings. It is made up of 14 items (7 for anxiety and 7 for depression), which are answered on a scale from 0 to 3, with maximum values of 21 in each of the subscales. Higher scores indicates the presence of anxiety and depression.
Quality of Life scores using EORTC QLQ C-30.
EORTC QLQ C-30 (version 3), this is an instrument developed to assess the quality of life in cancer patients using 30 questions that refer to the quality of life experienced by the patient during the last week. The first twenty-eight items include questions about different symptoms and are answered on a scale that ranges from 1 (not at all) to 4 (a lot), while the last two ask patients about the perception of their global health and quality of life in a scale from 1 (terrible) to 7 (excellent). The different items are grouped into functional scales (physical / role / emotional / cognitive / social and global) and symptom scale (fatigue / nausea and vomiting / dyspnea / sleep problems / loss of appetite / constipation / diarrhea and financial impact ). Higher scores indicates a better function.

Full Information

First Posted
December 28, 2021
Last Updated
October 31, 2022
Sponsor
Universidad de Córdoba
search

1. Study Identification

Unique Protocol Identification Number
NCT05289258
Brief Title
Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments
Official Title
Effectiveness of Cognitive Rehabilitation and the Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 25, 2022 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Córdoba

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background: Cognitive impairment appears frequently in cancer survivors, negatively affecting the quality of life and emotional well-being of patients. This study compares the effectiveness of a well-established treatment (cognitive rehabilitation) with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to alleviate these cognitive deficits and evaluate its effect on anxiety-depressive symptoms and the quality of life of survivors. Methods: A three-arm randomized superiority clinical trial, with a pre-post and follow-up repeated measures and intergroup design with a 1:1:1 allocation ratio will be carried out. A hundred and twenty-three breast cancer survivors with mild to moderate cognitive impairment will be randomly assigned to one of the interventions of the study: cognitive rehabilitation intervention group, an intervention group with UP intervention, or a control group on the waiting list. The primary outcome is to observe a significant improvement in cognitive function and quality of life in both intervention groups and a significant decrease in emotional impairments in comparison with the waitlist group. These results will be maintained at six months of follow-up. Discussion: The aim of this work is to test the efficacy of the Unified Barlow Protocol in reducing cognitive deficits in breast cancer survivors. The results of this trial may be useful in reducing the presence of cognitive problems in survivors and improving their emotional state and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Breast
Keywords
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), cognitive impairments, quality of life, anxiety and depression.

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This study is a three-arm randomized clinical trial, with a pre-post-follow-up repeated measures intergroup design.
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
123 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Neuropsychological treatment
Arm Type
Active Comparator
Arm Description
Combination of different neuropsychological rehabilitation programs
Arm Title
Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).
Arm Type
Experimental
Arm Description
This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED).
Arm Title
Waitlist group
Arm Type
Other
Arm Description
The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
Intervention Type
Behavioral
Intervention Name(s)
Neuropsychological treatment
Intervention Description
combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
Intervention Type
Behavioral
Intervention Name(s)
Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).
Intervention Description
This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
Intervention Type
Behavioral
Intervention Name(s)
Waitlist group
Intervention Description
The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
Primary Outcome Measure Information:
Title
Functional assessment of Cancer Therapy-Cognitive Function, version 3. (FACT-Cog).
Description
This is an instrument developed to assess chemotherapy-induced cognitive problems in cancer patients. It includes four different subscales: Perceived Cognitive Impairments (score range from 0-72), Impact of Perceived Cognitive Impairments on QoL (score range from 0-16), Comments from Others (score range from 0-16), and Perceived Cognitive Abilities (scores range from 0-28) that are scored using a Likert scale of five points from 0 (never) to 4 (several times a day). The higher the score, the better the cognitive function
Time Frame
Change of mean scores from baseline to immediately after intervention
Title
Memory Failures Everyday (MFE-30).
Description
It is a unifactorial questionnaire that measures a single construct: "cognitive complaints". It is made up of 30 items that are answered on a 5-point Likert scale from 1 (never) to 4 (always or almost always) with higher scores indicate poorer memory function. Scores are from 1 to with higher scores indicating higher memory impairments
Time Frame
Change of mean scores from baseline to immediately after intervention
Title
Hopkins Verbal Learning Test-Revised (HVLT-R).
Description
This test measures primary and secondary memory, the rate of verbal learning throughout three trials, as well as three forms of mnesic organization: serial ordering, semantic grouping, and subjective organization. The test consists of a list of 12 words that are presented orally at a speed of one word for every two seconds. a higher number of words is interpreted as better recall and recognition
Time Frame
Change of mean scores from baseline to immediately after intervention
Title
Trail Making Test (TMT).
Description
The TMT consists of two parts: Part A measures attention, processing speed, visual search, and working memory; on the other hand, part B is used to measure attention, executive function (cognitive flexibility, ability to change tasks, coordination of categories), working memory, visual-motor skills and processing speed. A greater time to complete the tasks is interpreted as a greater deterioration
Time Frame
Change of mean scores from baseline to immediately after intervention
Title
Controlled Oral Word Association Test (COWAT).
Description
The COWAT is a test that measures verbal fluency and is a recognized and sensitive indicator of cognitive functioning. the participant has to say as many words as possible in one minute, and a greater number of words is associated with greater verbal fluency.
Time Frame
Change of mean scores from baseline to immediately after intervention
Secondary Outcome Measure Information:
Title
Hospital Anxiety and Depression Scale (HADS)
Description
This scale is used to assess anxiety and depression in a hospital settings. It is made up of 14 items (7 for anxiety and 7 for depression), which are answered on a scale from 0 to 3, with maximum values of 21 in each of the subscales. Higher scores indicates the presence of anxiety and depression.
Time Frame
Change of mean scores from baseline to immediately after intervention]
Title
Quality of Life scores using EORTC QLQ C-30.
Description
EORTC QLQ C-30 (version 3), this is an instrument developed to assess the quality of life in cancer patients using 30 questions that refer to the quality of life experienced by the patient during the last week. The first twenty-eight items include questions about different symptoms and are answered on a scale that ranges from 1 (not at all) to 4 (a lot), while the last two ask patients about the perception of their global health and quality of life in a scale from 1 (terrible) to 7 (excellent). The different items are grouped into functional scales (physical / role / emotional / cognitive / social and global) and symptom scale (fatigue / nausea and vomiting / dyspnea / sleep problems / loss of appetite / constipation / diarrhea and financial impact ). Higher scores indicates a better function.
Time Frame
Change of mean scores from baseline to immediately after intervention]

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cancer diagnosis, stages I-III. Cancer type: Breast. Have received the last chemotherapy session in the last 6 months and a maximum of 6 years of treatment completion. Probable or mild to moderate cognitive impairment (score between 26 and 10 points according to the MMSE). Ability to be fluent in Spanish. Not currently participating in another clinical trial. Not currently receiving other psychological treatment Exclusion Criteria: Men and women aged > 70 years. Diagnosis of cancer, stage IV or other types of cancer. Last chemotherapy session < 6 months or > 6 years. No cognitive impairment (MMSE score between 30 and 27 points). Diagnosis of mental disorder (including substance abuse) prior to cancer diagnosis. Relapse in disease after chemotherapy treatment is completed. Neurodevelopmental Disorder Diagnosis. Diagnosis of diseases that affect cognitive performance such as: hypertension, cardiac diseases, epilepsy, dementias, multiple sclerosis, functional disorders (fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, post-concussion syndrome, whiplash syndrome), CNS infections (HIV, encephalitis), metabolic disorders (diabetes, B12 deficiency), obstructive sleep apnea, brain damage (stroke, TBI, CNS cancer) and use of medications / substances that interfere with cognitive function such as pregabalin, gabapentin, topiramate, antidepressants tricyclics, sodium valproate, anticholinergics, methylphenidate, typical antipsychotics.
Facility Information:
Facility Name
Hospital Universitario Reina Sofía
City
Córdoba
ZIP/Postal Code
14005
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Enrique Aranda, PhD
Phone
957 011 638
Email
earandaa@seom.org
Facility Name
Reina Sofía University Hospital
City
Córdoba
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francisco Garcia Torres, PhD
Phone
+3495721
Ext
8847
Email
z12gatof@uco.es
First Name & Middle Initial & Last Name & Degree
Francisco García-Torres, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
not applicable for this trial
Citations:
PubMed Identifier
36175973
Citation
Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E. Effectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled trial. Trials. 2022 Sep 30;23(1):819. doi: 10.1186/s13063-022-06731-w.
Results Reference
derived

Learn more about this trial

Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments

We'll reach out to this number within 24 hrs